DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Capital Group Dan Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on ...

Financial Performance - For the six months ended June 30, 2023, the net loss was $9.7 million, compared to $6.9 million for the same period in 2022, reflecting an increase in operating expenses primarily due to R&D activities [80]. - The company reported a net cash used in operating activities of $10.1 million for the six months ended June 30, 2023, compared to $6.4 million for the same period in 2022 [93]. - Net cash used in investing activities was $25.6 million for the six months ended June 30, 2023, compared to net cash provided of $4.7 million in 2022, primarily due to the timing of marketable securities transactions [94]. - Net cash provided by financing activities was $36.8 million for the six months ended June 30, 2023, compared to a net cash usage of $3 thousand for the same period in 2022 [95]. Research and Development - Research and Development (R&D) expenses increased to $2.5 million for the three months ended June 30, 2023, up from $2.0 million for the same period in 2022, and $6.2 million for the six months ended June 30, 2023, up from $3.9 million in 2022 [89]. - The company has incurred losses while advancing the R&D of its DM199 product candidate and has not generated any revenues from product sales [96]. - The company expects substantial additional capital will be needed to further R&D activities and clinical studies for DM199 [97]. Cash Position and Funding - As of June 30, 2023, the company had cash, cash equivalents, and marketable securities totaling $60.7 million, an increase from $33.5 million as of December 31, 2022 [92]. - The company generated $36.9 million in net proceeds from private placements in April and June 2023, which contributed to the increase in cash resources [80]. - The company expects its monthly negative cash flow to increase as it resumes the ReMEDy2 trial, but current cash resources are projected to be sufficient for at least the next 12 months [81]. - Current cash resources are expected to be sufficient to resume the ReMEDy2 trial and fund operations for at least the next twelve months [97]. - The company has historically financed operations primarily through sales of equity securities and expects to continue this practice [99]. - If additional capital is raised through equity or convertible debt securities, shareholder ownership interests will be diluted [100]. - The company may need to scale back operations if adequate funding is not available, which could include cost reduction strategies and licensing rights to third parties [101]. Clinical Trials - The ReMEDy2 trial aims to enroll approximately 350 patients across 75 sites in the U.S., focusing on patients with acute ischemic stroke who currently have limited treatment options [75]. - The FDA lifted the clinical hold on the ReMEDy2 trial in June 2023, allowing the company to resume preparations for the trial [76]. Administrative Expenses - General and Administrative (G&A) expenses were $2.2 million for the three months ended June 30, 2023, up from $1.4 million in 2022, and $4.1 million for the six months ended June 30, 2023, compared to $3.0 million in 2022 [90]. Accounting Policies - There have been no material changes to critical accounting policies and estimates from the previous annual report [102].

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2023 Conference Call. An audio recording of the webcast will be available shortl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from ________________ to ________________ Commission File Number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. (Exac ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics ReMEDy2 Update Conference C ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or Commission file number: 001-36291 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Britis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Elemer Piros - ROTH Capital Partners Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Ther ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-36291 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Br ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer & Co. Inc. Elemer Piros - ROTH Capital Partners Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2022 ...